Centric Wealth Management’s Agile Therapeutics AGRX Stock Holding History

Centric Wealth Management’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5	Closed	-$5K	–	174
2021 Q4	$5K	Hold	5	–	–	﹤0.01%	153
2021 Q3	$10K	Hold	5	–	–	﹤0.01%	152
2021 Q2	$13K	Hold	5	–	–	﹤0.01%	149
2021 Q1	$21K	Hold	5	–	–	0.01%	209
2020 Q4	$29K	Hold	5	–	–	0.01%	195
2020 Q3	$11K	Hold	5	–	–	0.01%	115
2020 Q2	$28K	Hold	5	–	–	0.01%	140
2020 Q1	$11K	Buy	+5	New	+$28.7K	0.01%	115
2019 Q4	–	Sell	-5	Closed	-$11K	–	136
2019 Q3	$11K	Hold	5	–	–	0.01%	115
2019 Q2	$15K	Hold	5	–	–	0.01%	110
2019 Q1	$15K	Hold	5	–	–	0.01%	96
2018 Q4	$6K	Buy	+5	New	+$7.66K	0.01%	111

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centric Wealth Management's AGRX Position: Q1 2022 in Review

Centric Wealth Management sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 5 shares — an estimated $5K sold.

Centric Wealth Management first reported a position in AGRX in Q4 2018 and held it in 12 quarters. The position peaked at $29K in Q4 2020. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

Centric Wealth Management reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
Centric Wealth Management sold 5 Agile Therapeutics shares in Q1 2022, an estimated $5K.
Centric Wealth Management first reported a position in Agile Therapeutics in Q4 2018 and held it in 12 quarters.
Centric Wealth Management's Agile Therapeutics position peaked at $29K in Q4 2020.
36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on Centric Wealth Management's 13F filing for Q1 2022, filed 5 Apr 2022.